SecurityPRSS / CafePress Inc. (12769A103)
IndustryMiscellaneous Retail
Common Shares Outstanding16,986,189 shares (as of 2018-03-31)
Total Insiders31
Total Directors11
Total Officers7

Stock Insider Trading (from SEC Form 4)

CafePress Inc. insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

PRSS / CafePress Inc. insiders include Durham Fred E. III, LEONE DOUGLAS M, MILLER LLOYD I III, MORITZ MICHAEL J, Furber Laurie, and ALLEN ANTHONY C, SEQUOIA CAPITAL IX, Arico Mary Ann, SEQUOIA CAPITAL FRANCHISE PARTNERS LP, Milliner Philip, SUBIN NEIL S, Standard General L.P., Kim Soohyung, SEQUOIA TECHNOLOGY PARTNERS XI, SEQUOIA CAPITAL ENTERPRENEURS ANNEX FUND, SCFF MANAGEMENT LLC, CONNOLLY PAT, SC XI MANAGEMENT LLC, Jackson Garett, MCBRIDE KENNETH THOMAS, Shannon Roger D, Swinmurn Nick, Barton Robert D, Howe Alan B Lysonge Ekumene M, SEQUOIA CAPITAL FRANCHISE FUND LP, Jain Maheesh, SC IX.I MANAGEMENT, LLC, SEQUOIA CAPITAL XI PRINCIPALS FUND, SEQUOIA CAPITAL XI, Buss Brad W, .

Insider Roster

Insider Dir Off 10% Shares Owned
Howe Alan B Director
X 50,000
ALLEN ANTHONY C Director
X 98,062
Arico Mary Ann Director
X 76,119
MCBRIDE KENNETH THOMAS Director
X 98,062
Durham Fred E. III Chief Executive Officer, Director, 10% Owner
X X X 2,725,431
Milliner Philip CFO
X 49,230
Lysonge Ekumene M VP, General Counsel, Secretary
X 49,587
SUBIN NEIL S 10% Owner
X 3,396,420
Barton Robert D Chief Operating Officer
X 333
Kim Soohyung See Footnote 3, Director, 10% Owner
Standard General L.P. 10% Owner
X X X 5,000,000
Furber Laurie Director
X 13,779
LEONE DOUGLAS M 10% Owner
MORITZ MICHAEL J 10% Owner
SC XI MANAGEMENT LLC 10% Owner
X 0
SCFF MANAGEMENT LLC 10% Owner
SC XI MANAGEMENT LLC 10% Owner
SEQUOIA CAPITAL ENTERPRENEURS ANNEX FUND 10% Owner
SEQUOIA CAPITAL FRANCHISE FUND LP 10% Owner
SEQUOIA CAPITAL FRANCHISE PARTNERS LP 10% Owner
SEQUOIA CAPITAL IX 10% Owner
SEQUOIA CAPITAL XI 10% Owner
SEQUOIA CAPITAL XI PRINCIPALS FUND 10% Owner
SEQUOIA TECHNOLOGY PARTNERS XI 10% Owner
SC IX.I MANAGEMENT, LLC 10% Owner
X 0
MORITZ MICHAEL J 10% Owner
LEONE DOUGLAS M 10% Owner
SC XI MANAGEMENT LLC 10% Owner
X 39,738
SEQUOIA CAPITAL FRANCHISE PARTNERS LP 10% Owner
SC IX.I MANAGEMENT, LLC 10% Owner
SCFF MANAGEMENT LLC 10% Owner
SEQUOIA TECHNOLOGY PARTNERS XI 10% Owner
SEQUOIA CAPITAL XI PRINCIPALS FUND 10% Owner
SEQUOIA CAPITAL XI 10% Owner
SEQUOIA CAPITAL IX 10% Owner
SEQUOIA CAPITAL FRANCHISE FUND LP 10% Owner
SEQUOIA CAPITAL ENTERPRENEURS ANNEX FUND 10% Owner
SC XI MANAGEMENT LLC 10% Owner
X 39,738
MILLER LLOYD I III 10% Owner
X 3,359,535
Shannon Roger D Director
X 26,119
Swinmurn Nick Director
X 48,062
CONNOLLY PAT Director
X 125,288
Jain Maheesh Chief Marketing Officer, 10% Owner
X X
Jackson Garett Chief Financial Officer
X
Buss Brad W Director
X

Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.

Tran
Date
Form Insider Code 10b-5 Direct Share
Price
Shares
Changed
Remaining
Shares
Post Value
2018-05-08 4 MCBRIDE KENNETH THOMAS A D 50,000 98,062
2018-05-08 4 Arico Mary Ann A D 1.40 50,000 76,119
2018-05-08 4 ALLEN ANTHONY C A D 1.40 50,000 98,062
2018-05-08 4 Howe Alan B A D 1.40 50,000 50,000
2018-05-01 4 Lysonge Ekumene M A D 1.46 21,500 49,587
2018-05-01 4 Milliner Philip A D 1.46 21,500 49,230
2018-05-01 4 Durham Fred E. III A D 1.46 180,000 2,725,431
2018-04-03 4 Lysonge Ekumene M F D 1.35 -825 28,087
2018-03-02 4 Milliner Philip F D 1.37 -378 27,730
2018-02-16 4 Lysonge Ekumene M F D 1.50 -582 28,912
2018-01-03 4 Barton Robert D F D 1.85 -863 333
2018-01-03 4 Milliner Philip F D 1.85 -2,996 28,108
2018-01-03 4 Lysonge Ekumene M F D 1.85 -1,771 29,494
2017-12-01 4 Milliner Philip F D 1.80 -334 31,104
2017-10-03 4 Barton Robert D F D 1.81 -825 1,196
2017-11-20 4 Lysonge Ekumene M F D 1.85 -534 31,265
2017-10-03 4 Lysonge Ekumene M F D 1.81 -757 31,799
2017-10-03 4 Milliner Philip F D 1.81 -980 31,438
2017-09-29 4 SC XI MANAGEMENT LLC S I 1.7529 -39,738 0
2017-09-29 4 SC XI MANAGEMENT LLC S I 1.7529 -136,865 0
2017-09-29 4 SC XI MANAGEMENT LLC S I 1.7529 -1,258,026 0
2017-09-29 4 SC XI MANAGEMENT LLC S I 1.7529 -393,497 0
2017-09-29 4 SC XI MANAGEMENT LLC S I 1.7529 -122,968 0
2017-09-29 4 SC XI MANAGEMENT LLC S I 1.7529 -901,768 0
2017-09-29 4 SC XI MANAGEMENT LLC S I 1.7529 -16,396 0
2017-09-29 4 SC XI MANAGEMENT LLC S I 1.7529 -39,738 0
2017-09-29 4 SC XI MANAGEMENT LLC S I 1.7529 -136,865 0
2017-09-29 4 SC XI MANAGEMENT LLC S I 1.7529 -1,258,026 0
2017-09-29 4 SC XI MANAGEMENT LLC S I 1.7529 -393,497 0
2017-09-29 4 SC XI MANAGEMENT LLC S I 1.7529 -122,968 0
2017-09-29 4 SC XI MANAGEMENT LLC S I 1.7529 -901,768 0
2017-09-29 4 SC XI MANAGEMENT LLC S I 1.7529 -16,396 0
2017-09-21 4 Furber Laurie A D 2.08 133,779 13,779
2017-09-22 4 SC XI MANAGEMENT LLC S I -124 39,738
2017-09-22 4 SC XI MANAGEMENT LLC S I -427 136,865
2017-09-22 4 SC XI MANAGEMENT LLC S I -3,928 1,258,026
2017-09-22 4 SC XI MANAGEMENT LLC S I -1,229 393,497
2017-09-22 4 SC XI MANAGEMENT LLC S I -384 122,968
2017-09-22 4 SC XI MANAGEMENT LLC S I -2,815 901,768
2017-09-22 4 SC XI MANAGEMENT LLC S I -51 16,396
2017-09-21 4 SC XI MANAGEMENT LLC S I -10 39,862
2017-09-21 4 SC XI MANAGEMENT LLC S I -33 137,292
2017-09-21 4 SC XI MANAGEMENT LLC S I -307 1,261,954
2017-09-21 4 SC XI MANAGEMENT LLC S I -96 394,726
2017-09-21 4 SC XI MANAGEMENT LLC S I -30 123,352
2017-09-21 4 SC XI MANAGEMENT LLC S I -220 904,583
2017-09-21 4 SC XI MANAGEMENT LLC S I -4 16,447
2017-09-20 4 SC XI MANAGEMENT LLC S I 2.19 -331 39,872 87,320
2017-09-20 4 SC XI MANAGEMENT LLC S I 2.19 -1,138 137,325 300,742
2017-09-20 4 SC XI MANAGEMENT LLC S I 2.19 -10,465 1,262,261 2,764,352
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

3 of the Best Penny Stocks To Buy Right Now

2018-05-16 investorplace
Penny stocks get a bad rap — and it’s somewhat well-deserved. While a price below $5 might make a stock seem “cheap,” that’s actually not the case. An investor’s ownership of a company on a percentage basis, and the valuation of that company, is what matters. Whether a stock is priced at $4, $0.40, or $400 doesn’t in and of itself affect the potential gains — or losses — in that stock. The best penny stocks to buy shouldn’t be buys because of their price — but rather their value. (58-3)

CafePress' (PRSS) CEO Fred Durham on Q1 2018 Results - Earnings Call Transcript

2018-05-05 seekingalpha
Good day, everyone. Welcome to the CafePress First Quarter 2018 Earnings Conference Call. Today's conference is being recorded. (1-0)